No, prolonged use of Tylenol or naproxen does not cause low serum bilirubin
The evidence shows these medications affect bilirubin measurements in opposite ways—both can cause falsely elevated (not low) bilirubin readings through laboratory interference, and acetaminophen can cause actual liver injury with elevated bilirubin, but neither medication causes true low serum bilirubin levels.
Acetaminophen (Tylenol) Effects on Bilirubin
Acetaminophen causes hepatotoxicity with elevated bilirubin, not low bilirubin. The drug is dose-dependent hepatotoxin where most cases of acute liver failure occur with ingestions exceeding 10 gm/day, though severe injury can rarely occur with doses as low as 3-4 gm/day 1. When hepatotoxicity develops, you see:
- Elevated aminotransferases (AST/ALT often >3,500 IU/L)
- Elevated total and conjugated bilirubin as liver injury progresses
- Potential progression to acute liver failure with jaundice 1
The CDC guidelines specifically warn against concurrent acetaminophen use with other hepatotoxic medications, noting that monitoring should include bilirubin measurements, with drug discontinuation triggered when bilirubin concentration exceeds normal range 2.
Laboratory Interference with Acetaminophen
Acetaminophen can cause falsely elevated unbound bilirubin measurements when using the glucose oxidase-peroxidase (GOD-POD) method 3. However, this is measurement artifact, not true hyperbilirubinemia. Research demonstrates that acetaminophen accelerates the GOD-POD reaction without actually displacing bilirubin from albumin 4.
Naproxen Effects on Bilirubin
Naproxen causes laboratory interference that falsely elevates bilirubin readings, not low bilirubin. The FDA label for naproxen lists hepatic effects including borderline elevations in liver tests in up to 15% of patients, with notable ALT/AST elevations (≥3× upper limit of normal) in approximately 1% of patients 5. Rare cases of severe hepatic reactions including jaundice and hepatic failure have been reported.
Laboratory Interference with Naproxen
The naproxen metabolite O-desmethylnaproxen (ODMN) causes significant positive interference in certain bilirubin assays:
- Falsely elevated total bilirubin when using Jendrassik and Grof method (Beckman Coulter and Siemens assays) 6, 7, 8
- This occurs particularly with supratherapeutic naproxen doses
- Direct bilirubin measurements are not affected due to acidic pH of reagents 7
- The Roche bilirubin assay is not affected by this interference 8
A case report documented a patient with naproxen overdose showing elevated total bilirubin with normal direct bilirubin and no evidence of hemolysis, biliary obstruction, or hepatic dysfunction—the hyperbilirubinemia was purely laboratory artifact from ODMN interference 6.
Clinical Implications
If you encounter low serum bilirubin in a patient taking these medications:
This is not caused by acetaminophen or naproxen—look for other causes of low bilirubin (malnutrition, chronic disease, etc.)
If you see elevated bilirubin with these medications:
- With acetaminophen: Check aminotransferases, assess for hepatotoxicity, consider N-acetylcysteine if indicated
- With naproxen: Consider laboratory interference if direct bilirubin is normal and no clinical evidence of liver disease
- Repeat using alternative assay method (Roche assay for naproxen cases) 8
Monitor liver function in patients on prolonged NSAID therapy including naproxen, checking for signs of hepatotoxicity 5
Common Pitfall
Do not assume elevated bilirubin automatically represents true hyperbilirubinemia in patients taking naproxen—verify with direct bilirubin measurement and consider assay interference, especially with supratherapeutic doses 6, 7.